GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Überblick


Chris Bruno will speak on a panel for LSPN Connect on the topic of “GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?” Discussion will include an overview of the role of skinny labelling in the US FDA’s regulation of drug products and the implications of the recent GSK v Teva ruling on patent strategies for brand and generic drug manufacturers.

Click here for more information and to register.

Mehr erfahren

Chicago, Illinois / Externe Vorträge / September 1, 2021

2021 ACC Chicago Summit

Webinar / Externe Vorträge / June 24, 2021

Best Practices for Patent Quality

Webinar / Externe Vorträge / May 25, 2021

Intellectual Property and Cannabis

ANSPRECHPARTNER